Novartis AG is a Swiss-based healthcare company that focuses on the research, development, manufacturing, and marketing of innovative healthcare products globally.
The company's portfolio includes a range of prescription medicines for patients and healthcare professionals, addressing various therapeutic areas such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
In the field of oncology, Novartis offers Pluvicto, a targeted radioligand therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. Additionally, the company provides Lutathera, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
Novartis has established strategic partnerships to drive innovation and expand its product offerings. For instance, the company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy designed to reduce LDL cholesterol. Furthermore, Novartis has partnered with Dawn Health to develop and commercialize Ekiva, a digital solution for people living with Paroxysmal Nocturnal Hemoglobinuria.
With a rich history dating back to 1996, Novartis AG is headquartered in Basel, Switzerland, and continues to be a leader in the global healthcare industry. For more information, please visit their website at https://www.novartis.com.